Biomerica has revealed the validation of its inFoods IBS diagnostic test for use with finger stick (capillary) patient whole blood samples.

The validation helps simplify sample collection and pave the way for broader access to the test. 

The new finger stick blood collection option allows any trained medical professional to collect the patient’s blood sample and then send it to the lab for processing.

The test is provided as a laboratory-developed test conducted in a laboratory accredited by the College of American Pathologists and certified by Clinical Laboratory Improvement Amendments.

Biomerica chief commercial officer Robert Carlson said: “This advancement reflects our continued commitment to innovation and significantly expands the number of physician offices that can use the inFoods IBS system to create treatment protocols for their IBS patients.”

Designed to evaluate a patient’s above-normal immunoreactivity to specific foods, the InFoods IBS test utilises a simple blood collection procedure.

The InFoods IBS information empowers physicians to offer personalised recommendations to patients regarding specific foods that can be avoided to reduce symptoms associated with IBS such as bloating, pain, diarrhoea and constipation.

The clinical study for inFoods IBS was conducted at several institutions, comprising Mayo Clinic, Beth Israel Deaconess Medical Centre (a Harvard Medical School Teaching Hospital), the University of Michigan and Houston Methodist Hospital.

Biomerica CEO Zackary Irani said: “By enabling the use of finger stick whole blood samples, we’re making our personalized IBS therapy more convenient and easier than ever.

“This process reduces patient discomfort and facilitates wider access to the inFoods IBS test, allowing healthcare providers in a variety of settings to efficiently use inFoods IBS and initiate appropriate treatment plans.”